AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
5min chapter
Episode 097: Treatment of Relapsed/Refractory CLL
The Fellow on Call: The Heme/Onc Podcast
Navigating Toxic Therapies and Poor Prognoses in CLL
This chapter examines the withdrawal of idelalisib from the market due to safety issues and its ineffectiveness compared to standard therapies for CLL. It highlights the critical nature of Richter's transformation in CLL and the increasing importance of patient preferences and MRD-guided treatment approaches.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode